NZ707329A - Tetracycline compositions - Google Patents

Tetracycline compositions

Info

Publication number
NZ707329A
NZ707329A NZ707329A NZ70732911A NZ707329A NZ 707329 A NZ707329 A NZ 707329A NZ 707329 A NZ707329 A NZ 707329A NZ 70732911 A NZ70732911 A NZ 70732911A NZ 707329 A NZ707329 A NZ 707329A
Authority
NZ
New Zealand
Prior art keywords
compositions
divalent
disclosed
dimethylamino
tetracycline antibiotic
Prior art date
Application number
NZ707329A
Inventor
David C Griffith
Serge Boyer
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of NZ707329A publication Critical patent/NZ707329A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are pharmaceutical compositions comprising an aqueous solution of a 7-dimethylamino tetracycline antibiotic and a divalent or trivalent cation, preferably a magnesium cation, wherein the molar ratio of divalent or trivalent cation to the 7-dimethylamino-tetracycline antibiotic is greater than 2:1 and wherein the solution does not comprise a pharmaceutically acceptable oil, has a pH greater than 4 and less than 7, and is suitable for intravenous administration. Also disclosed are water soluble solid compositions which upon dissolution have these properties and methods and kits for producing such compositions.
NZ707329A 2010-05-12 2011-05-12 Tetracycline compositions NZ707329A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33410610P 2010-05-12 2010-05-12
US39230410P 2010-10-12 2010-10-12
NZ60378411 2011-05-12

Publications (1)

Publication Number Publication Date
NZ707329A true NZ707329A (en) 2016-09-30

Family

ID=56989721

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ707329A NZ707329A (en) 2010-05-12 2011-05-12 Tetracycline compositions

Country Status (1)

Country Link
NZ (1) NZ707329A (en)

Similar Documents

Publication Publication Date Title
UA105229C2 (en) Pharmaceutical formulation
IL203448A (en) Azabiphenylaminobenzoic acid derivatives for use in the treatment or prevention of a pathological condition or disease susceptible to amelioration by inhibition of dhodh and pharmaceutical compositions comprising them
MX347544B (en) Polycyclic lpa1 antagonist and uses thereof.
WO2010108074A3 (en) Inhibitors of pi3 kinase
MX2010006799A (en) Benzofuropyrimidinones as protein kinase inhibitors.
NZ601689A (en) Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms
IN2014MN02106A (en)
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
MX2016006197A (en) Formulations of azaindole compounds.
MX2009005413A (en) Crystalline forms of zoledronic acid.
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
IN2012DN00765A (en)
IN2012DN02502A (en)
TN2015000356A1 (en) Bicyclic compounds
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MX2012001691A (en) Orally disintegrating compositions of linaclotide.
AU2010275640A8 (en) Benzoquinolizinium salt derivatives as anticancer agents
TN2012000105A1 (en) Spirolactam derivatives and uses of same
WO2012038979A3 (en) A process for preparation of ertapenem
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX2013002620A (en) Novel n-hydroxy-benzamides for the treatment of cancer.
WO2014083580A3 (en) Pharmaceutical compositions of regadenoson
WO2014144407A8 (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
WO2011044375A3 (en) Apogossypolone derivatives as anticancer agents
WO2010023473A3 (en) Crystalline form of sunitinib and processes for its preparation

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 MAY 2018 BY AJ PARK

Effective date: 20170310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2019 BY CPA GLOBAL

Effective date: 20180329

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2020 BY COMPUTER PACKAGES INC

Effective date: 20190418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200418

ASS Change of ownership

Owner name: MELINTA THERAPEUTICS, INC., US

Effective date: 20210414

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2023 BY COMPUTER PACKAGES INC

Effective date: 20220417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAY 2024 BY COMPUTER PACKAGES INC

Effective date: 20230417